Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin in Advanced Prostate Cancer
NCT00003740Phase 2
Key facts
- Status
- Completed
- Start
- Oct 1998
- Primary completion
- Sep 2002
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- trastuzumab
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Time to Progression and Tumor Activity. Started Oct 1998; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Trastuzumab
Trastuzumab IV weekly
03
Who it enrols
Patients with histologically documented androgen dependent or independent prostate cancer who have progressed on primary hormonal treatment.
04
Endpoints
Primary
Time to Progression
Tumor Activity
Secondary
Post-therapy changes in PSA
Beyond the preview
Go deeper on NCT00003740.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003740.